BrightPath Biotherapeutics Co (TSE:4594) Marketable Securities: 円0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4594 BrightPath Biotherapeutics Co Ltd TSE:4594
47 GF Score
Price 円50.00
! 3 Warning Signs
View Full Analysis

What is BrightPath Biotherapeutics Co Marketable Securities?

BrightPath Biotherapeutics Co TSE:4594 47 Marketable Securities is 円0.00 Mil as of Mar. 2026. GuruFocus rates TSE:4594 with a GF Score™ of 47/100. The stock has 3 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. BrightPath Biotherapeutics Co's Marketable Securities for the quarter that ended in Mar. 2026 was 円0.00 Mil.

BrightPath Biotherapeutics Co  (TSE:4594) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

BrightPath Biotherapeutics Co Marketable Securities Related Terms

BrightPath Biotherapeutics Co Marketable Securities Historical Data

* Premium members only.

The historical data trend for BrightPath Biotherapeutics Co's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BrightPath Biotherapeutics Co Marketable Securities Chart

BrightPath Biotherapeutics Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BrightPath Biotherapeutics Co Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:4594
47GF Score
BrightPath Biotherapeutics Co Ltd TSE:4594
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BrightPath Biotherapeutics Co Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of 円0.00 Mil mean?
BrightPath Biotherapeutics Co (TSE:4594) has a Marketable Securities of 円0.00 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on BrightPath Biotherapeutics Co and its competitors.
Is BrightPath Biotherapeutics Co's Marketable Securities too high?
BrightPath Biotherapeutics Co's current Marketable Securities is 円0.00 Mil. Overall, BrightPath Biotherapeutics Co has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does BrightPath Biotherapeutics Co's Marketable Securities compare to VRTX and REGN?
BrightPath Biotherapeutics Co's Marketable Securities of 円0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on BrightPath Biotherapeutics Co and its competitors. BrightPath Biotherapeutics Co's current Marketable Securities is 円0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BrightPath Biotherapeutics Co stock overvalued right now?
BrightPath Biotherapeutics Co (TSE:4594) has a current Marketable Securities of 円0.00 Mil. The current Marketable Securities is 円0.00 Mil. BrightPath Biotherapeutics Co's overall GF Score™ is 47/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For BrightPath Biotherapeutics Co (TSE:4594), the current Marketable Securities is 円0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BrightPath Biotherapeutics Co Business Description

Address 2-2-4 Kojimachi, Kojimachi Central Building 7th Floor, Chiyoda-ku, Tokyo, JPN
BrightPath Biotherapeutics Co Ltd is a biopharmaceutical venture company. It is engaged in developing novel cancer immunotherapeutics. Its products include two candidate products: ITK-1 and GRN-1201 which are in the clinical trial stage.
47GF Score

Get the complete analysis for TSE:4594

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円50.00
Price